Navigation Links
Nu Skin Enterprises Enters Into Agreement To Acquire NOX Technologies
Date:11/14/2012

PROVO, Utah, Nov. 14, 2012 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS) announced today that it has signed an agreement to acquire NOX Technologies, Inc., a biotechnology and biodiagnostic company based in Malvern, Pennsylvania for $12.5 million. The agreement includes the acquisition of technology and patents, including previously licensed technology already utilized in connection with Nu Skin's anti-aging research efforts.

"The acquisition of NOX Technologies demonstrates our ongoing commitment to scientific innovation and provides us with additional tools to target the sources of aging," said Chief Scientific Officer Joe Chang, Ph.D. "Furthermore, we believe the acquisition will enhance our long-term pipeline of scientifically validated anti-aging solutions for health, beauty and wellness."

NOX Technologies provides Nu Skin scientists with a deeper understanding of the aging process and supports the company's ability to understand important sources of aging. arNOX, an age-related protein identified by NOX Technologies, is found on the cell surface and is capable of superoxide generation, a relevant aspect of the aging process.

According to Thomas B. Shelton, chief executive officer of NOX Technologies, "This merger is the culmination of many years of working with Nu Skin researchers on our arNOX technology. NOX Technologies' translation of the basic science around arNOX paved the way for this unique technology to be incorporated into Nu Skin's successful anti-aging research and development efforts."

The acquisition is subject to customary closing conditions, including approval of the transaction by the stockholders of NOX Technologies, Inc.  Closing is expected to occur prior to the end of 2012.

About NOX Technologies, Inc.
Established in 2003, NOX Technologies, Inc. is a biotechnology and biodiagnostic company focused on the identification, characterization and detection of cell surface proteins relating to aging. Through its research and development efforts, NOX Technologies identified agents that interact with age-related ECTO-NOX proteins (arNOX).

NOX Technologies' discovery of specific inhibitors of arNOX that potentially ameliorate skin damage and the signs of aging led to Nu Skin's development of specific skin care products that are useful for improving the youthful appearance of the skin.

About Nu Skin Enterprises, Inc.
Nu Skin Enterprises, Inc. demonstrates its tradition of innovation through its comprehensive anti-aging product portfolio, independent business opportunity and corporate social responsibility initiatives. The company's scientific leadership in both skin care and nutrition has established Nu Skin as a premier anti-aging company. The company's anti-aging products feature the new ageLOC® suite of products including the ageLOC®R2 nutritional supplement, ageLOC® Galvanic Spa System and ageLOC Galvanic Body Spa™, as well as the ageLOC® Transformation daily skin care system. A global direct selling company, Nu Skin operates in 53 markets worldwide and has more than 900,000 active distributors and preferred customers. Nu Skin is traded on the New York Stock Exchange under the symbol 'NUS'. More information is available at http://www.nuskin.com.

Please Note: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations and beliefs regarding the company's acquisition of NOX Technologies, Inc.; statements regarding acquisition timing, terms and conditions; statements regarding the impact of the acquisition on the company's scientific research and product development efforts; statements regarding the company's plans and strategies; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "project," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "could," "may," "might," the negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

  • risks that the acquisition may not be completed or may cost more or take longer to complete than anticipated; and
  • risks related to the company's ability to effectively integrate and utilize NOX Technologies, Inc. in the company's scientific research and product development efforts.

The forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission.  The forward-looking statements set forth the company's beliefs as of the date that such information was first provided and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.


'/>"/>
SOURCE Nu Skin Enterprises, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Centers for Medicare & Medicaid Services Win 2012 National Cybersecurity Innovation Award
2. Top 10 “Best Children’s Hospitals” Include 3 Pediatric Centers Offering SynCardia Total Artificial Heart
3. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
4. Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy
5. Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimers Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
6. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
7. Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife
8. The Trendlines Group Announces Co-development Agreement with Endo
9. No on Prop. 37: French Rat Study Author Made Reporters Sign Confidentiality Agreements Prohibiting them from Consulting Independent Scientific Experts
10. LLSs Lead Therapy Acceleration Program in MDS Gets Boost from Major Industry Licensing Agreement
11. Islet Sciences Announces Exclusive License Agreement with the University of California (UCLA) to Commercialize Small Molecules for Islet Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... ... Mitotech S.A, a Luxembourg based clinical stage biotechnology company, announced positive results of ... devastating genetic disease that leads to a sudden and rapid loss of central vision. ... 11778, 14484 and 3460 mutations and having experienced the onset of symptoms more than ...
(Date:4/27/2017)... Yorba Linda, Ca (PRWEB) , ... April 27, ... ... will hear from a practicing internist, who will review how testing for 1,25-Dihydroxyvitamin ... signs that prompt ordering of 25-OH-vitamin D and 1,25 dihydroxyvitamin D. , Dr. ...
(Date:4/27/2017)... ... April 27, 2017 , ... Volunteers supported by ... engineers, and industry professionals in visiting U.S. Congressional offices in Washington, D.C., yesterday ... world photonics industry. , This year, National Photonics Initiative (NPI) Congressional ...
(Date:4/27/2017)... 27, 2017  Kinexum, a distinguished resource for research, ... the appointment of Thomas C. Seoh as ... M.D., Kinexum founder, who becomes Executive Chairman and will ... clients. Thomas Seoh commented, "I ... mission and lead the firm,s remarkable team of life ...
Breaking Biology Technology:
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based and ... 2022", published by MarketsandMarkets, the market is expected to be worth USD 18.98 ... Continue Reading ... ...      ...
(Date:3/22/2017)... VILNIUS, Lithuania , March 21, 2017 /PRNewswire/ ... identification and object recognition technologies, today announced the ... development kit (SDK), which provides improved facial recognition ... safety cameras on a single computer. The new ... algorithms to improve accuracy, and it utilizes a ...
(Date:3/22/2017)... , March 21, 2017 Vigilant ... company serving law enforcement agencies, announced today the appointment ... as director of public safety business development. ... law enforcement experience, including a focus on the aviation ... his most recent position, Mr. Sheridan served as the ...
Breaking Biology News(10 mins):